Mizuho Lifts PT on Pediatrix Medical Group (MD) Following Q1 Results
Key takeaways
- (NYSE:MD) also reported that net income came up to $30 million and adjusted EBITDA was $58 million.
- (NYSE:MD) provides physician services, including neonatal care, maternal fetal care, and other pediatric subspecialty care.
- While we acknowledge the potential of MD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
Mizuho Lifts PT on Pediatrix Medical Group (MD) Following Q1 Results Noor Ul Ain Rehman Thu, May 14, 2026 at 11:53 PM GMT+7 2 min read MD Pediatrix Medical Group, Inc. (NYSE:MD) is one of the best small cap stocks to buy for 10x potential. Mizuho lifted the price target on Pediatrix Medical Group, Inc. (NYSE:MD) to $24 from $21 on May 8, maintaining a Neutral rating on the shares. The rating update came after the company announced financial results for fiscal Q1 2026, reporting earnings of $0.36 per share for the three months ended March 31, 2026. On a non-GAAP basis, adjusted EPS came up to $0.44.
Pediatrix Medical Group, Inc. (NYSE:MD) also reported that net income came up to $30 million and adjusted EBITDA was $58 million. Net revenue was $476 million for the quarter compared to $458.4 million for the prior-year period, with the increase reflecting growth in same-unit revenue of 2.8%, and to a lesser extent, growth in non-same unit activity. Management attributed this to recent acquisitions and was partially offset by practice dispositions. In addition, Pediatrix Medical Group, Inc. (NYSE:MD) reported that same-unit revenue from net reimbursement-related factors rose by 4.4% for fiscal Q1 2026, as compared to the prior-year period.
Pediatrix Medical Group, Inc. (NYSE:MD) provides physician services, including neonatal care, maternal fetal care, and other pediatric subspecialty care.